Zoryve (Roflumilast) Patent Expiration, LOE Window & CMS Spending

Zoryve (Roflumilast) by Arcutis Biotherapeutics: FDA Orange Book LOE 2037-08-25, 9 AB generics, $53.3M 2024 CMS Part D & Medicaid spend, and $965 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorArcutis Biotherapeutics
FDA Application & PathwayN215985 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2037-08-25
Orange Book Patents (*PED Extensions)18 patents (0 *PED)
Active AB-Rated Generic Competitors9
2024 CMS Total Public Spend$53.3M
2024 Medicare Part D Spend$25.6M
2024 Medicaid Spend$27.7M
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($965 intro WAC)